KOD, US50015M1099

Kodiak Sciences stock reports wider Q3 loss as cash supports 2027

Published on 11/17/2026 at 22:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Kodiak Sciences stock follows third-quarter results showing a wider net loss and new clinical milestones. Management expects cash to support operations into 2027.

Quarterly Loss And Pipeline Milestones

  • Kodiak reported a third-quarter 2026 net loss of USD 66.2 million and held USD 88.7 million in cash at September 30.
  • The company plans a multi-indication Zenkuda BLA by year-end 2026 and expects initial KSI-101 PEAK data in December.
  • Net proceeds of USD 69 million from an ATM offering lifted funding visibility into 2027.
KOD, US50015M1099, Illustration mit AI erstellt.

Kodiak Sciences reported a wider third-quarter loss on November 12, while advancing its retina drug pipeline and raising additional capital. The company said in its quarterly release that net loss for the period ended September 30 was USD 66.2 million, compared with USD 61.5 million a year earlier.

Research and development expenses rose to USD 58.3 million from USD 50.5 million as Kodiak continued clinical and manufacturing work for its PEAK, PINNACLE and ALTO programs. General and administrative expenses fell to USD 8.8 million from USD 11.9 million. The quarterly loss included USD 12.8 million in non-cash stock-based compensation.

Pipeline Moves Toward Regulatory Filings

Management said Zenkuda, or tarcocimab tedromer, met the primary endpoint in the Phase 3 DAYBREAK study in wet age-related macular degeneration. The company reported a p-value of 0.0007 and said 54% of patients were on six-month dosing. Kodiak plans to submit a multi-indication biologics license application for Zenkuda in the fourth quarter of 2026, covering wet AMD, diabetic retinopathy and retinal vein occlusion.

Tabirafusp-ted, also known as KSI-501, met its vision primary endpoint in DAYBREAK, with a reported p-value of 0.0036. The treatment is now being evaluated in the Phase 3 ALTO study in diabetic macular edema.

KSI-101 remains on track for a first pivotal PEAK readout in December 2026. Kodiak said enrollment of the first 300-patient cohort was complete, while topline data from a second 600-patient cohort across PEAK and PINNACLE are anticipated in the second quarter of 2027.

Capital Supports Development Plans

Kodiak ended September with USD 88.7 million in cash and cash equivalents. After quarter-end, it raised aggregate net proceeds of USD 69 million through sales of common stock under its at-the-market facility. Management expects the current cash position to support current and planned operations into 2027.

Kodiak Sciences stock traded at 88.25 euros on Lang & Schwarz at 22:46 CET on Tuesday, November 17.

Kodiak Sciences Inc.

  • Company: Kodiak Sciences Inc.
  • ISIN: US50015M1099
  • Ticker: KOD
  • Home exchange: Nasdaq
  • Quarter: Third quarter 2026, ended September 30
  • Lang & Schwarz quote: 88.25 euros on November 17, 2026 at 22:46 CET

The broader market context is covered by the S&P 500.

More news and analyses on Kodiak Sciences stock

Disclaimer...
en | US50015M1099 | KOD | boerse | 70528798 | bgmi